Selected research
Industry Research
Heparin Sodium API Industry Research Report 2026
Market perspective
The global Heparin Sodium API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Heparin Sodium API is forecast to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Heparin Sodium API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Heparin Sodium API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Heparin Sodium API include , among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Heparin Sodium API market in revenue (US$ million) and, where applicable, sales volume (t), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of types and applications, harmonizes vendor attribution, and presents comparable time series by company, type, application, and region/country, including indicative price bands (US$/t) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for manufacturers, new entrants, channel partners, and investors; the report also reviews technology shifts and notable product introductions relevant to Heparin Sodium API.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Heparin Sodium API Market by Company
Aspen Oss
Bioibérica
Opocrin
Pfizer
Hebei Changshan Biochemical Pharmaceutical
Cisen Pharmaceutical
Yantai Dongcheng Pharmaceutical
Shenzhen Hepalink Pharmaceutical
Hubei Enoray Biopharmaceutical
Nanjing King-friend Biochemical Pharmaceutical
Qingdao Jiulong Biopharmaceutical
Changzhou Qianhong Biopharma
Dongying Tiandong Pharmaceutical
Nanjing Xinbai Pharmaceutical
Yino Pharma
Heparin Sodium API Segment by Type
Unfractionated Heparin Sodium
Low Molecular Heparin Sodium
Heparin Sodium API Segment by Application
Cardiovascular Disease
Dialysis Anticoagulation
Postoperative Thrombosis Prevention
Other
Heparin Sodium API Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Heparin Sodium API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Heparin Sodium API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Heparin Sodium API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Heparin Sodium API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Heparin Sodium API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Heparin Sodium API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Unfractionated Heparin Sodium
- Low Molecular Heparin Sodium
Applications
- Cardiovascular Disease
- Dialysis Anticoagulation
- Postoperative Thrombosis Prevention
- Other
Companies covered
- Aspen Oss
- Bioibérica
- Opocrin
- Pfizer
- Hebei Changshan Biochemical Pharmaceutical
- Cisen Pharmaceutical
- Yantai Dongcheng Pharmaceutical
- Shenzhen Hepalink Pharmaceutical
- Hubei Enoray Biopharmaceutical
- Nanjing King-friend Biochemical Pharmaceutical
- Qingdao Jiulong Biopharmaceutical
- Changzhou Qianhong Biopharma
- Dongying Tiandong Pharmaceutical
- Nanjing Xinbai Pharmaceutical
- Yino Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Heparin Sodium API by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.2.2 Unfractionated Heparin Sodium
- 2.2.3 Low Molecular Heparin Sodium
- 2.3 Heparin Sodium API by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Cardiovascular Disease
- 2.3.3 Dialysis Anticoagulation
- 2.3.4 Postoperative Thrombosis Prevention
- 2.3.5 Other
- 2.4 Global Market Growth Prospects
- 2.4.1 Global Heparin Sodium API Production Value Estimates and Forecasts (2021-2032)
- 2.4.2 Global Heparin Sodium API Production Capacity Estimates and Forecasts (2021-2032)
- 2.4.3 Global Heparin Sodium API Production Estimates and Forecasts (2021-2032)
- 2.4.4 Global Heparin Sodium API Market Average Price (2021-2032)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Heparin Sodium API Production by Manufacturers (2021-2026)
- 3.2 Global Heparin Sodium API Production Value by Manufacturers (2021-2026)
- 3.3 Global Heparin Sodium API Average Price by Manufacturers (2021-2026)
- 3.4 Global Heparin Sodium API Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Heparin Sodium API Key Manufacturers, Manufacturing Sites & Headquarters
- 3.6 Global Heparin Sodium API Manufacturers, Product Type & Application
- 3.7 Global Heparin Sodium API Manufacturers Established Date
- 3.8 Global Heparin Sodium API Market CR5 and HHI
- 3.9 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Aspen Oss
- 4.1.1 Aspen Oss Heparin Sodium API Company Information
- 4.1.2 Aspen Oss Heparin Sodium API Business Overview
- 4.1.3 Aspen Oss Heparin Sodium API Production Capacity, Value and Gross Margin (2021-2026)
- 4.1.4 Aspen Oss Product Portfolio
- 4.1.5 Aspen Oss Recent Developments
- 4.2 Bioibérica
- 4.2.1 Bioibérica Heparin Sodium API Company Information
- 4.2.2 Bioibérica Heparin Sodium API Business Overview
- 4.2.3 Bioibérica Heparin Sodium API Production Capacity, Value and Gross Margin (2021-2026)
- 4.2.4 Bioibérica Product Portfolio
- 4.2.5 Bioibérica Recent Developments
- 4.3 Opocrin
- 4.3.1 Opocrin Heparin Sodium API Company Information
- 4.3.2 Opocrin Heparin Sodium API Business Overview
- 4.3.3 Opocrin Heparin Sodium API Production Capacity, Value and Gross Margin (2021-2026)
- 4.3.4 Opocrin Product Portfolio
- 4.3.5 Opocrin Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Heparin Sodium API Company Information
- 4.4.2 Pfizer Heparin Sodium API Business Overview
- 4.4.3 Pfizer Heparin Sodium API Production Capacity, Value and Gross Margin (2021-2026)
- 4.4.4 Pfizer Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 Hebei Changshan Biochemical Pharmaceutical
- 4.5.1 Hebei Changshan Biochemical Pharmaceutical Heparin Sodium API Company Information
- 4.5.2 Hebei Changshan Biochemical Pharmaceutical Heparin Sodium API Business Overview
- 4.5.3 Hebei Changshan Biochemical Pharmaceutical Heparin Sodium API Production Capacity, Value and Gross Margin (2021-2026)
- 4.5.4 Hebei Changshan Biochemical Pharmaceutical Product Portfolio
- 4.5.5 Hebei Changshan Biochemical Pharmaceutical Recent Developments
- 4.6 Cisen Pharmaceutical
- 4.6.1 Cisen Pharmaceutical Heparin Sodium API Company Information
- 4.6.2 Cisen Pharmaceutical Heparin Sodium API Business Overview
- 4.6.3 Cisen Pharmaceutical Heparin Sodium API Production Capacity, Value and Gross Margin (2021-2026)
- 4.6.4 Cisen Pharmaceutical Product Portfolio
- 4.6.5 Cisen Pharmaceutical Recent Developments
- 4.7 Yantai Dongcheng Pharmaceutical
- 4.7.1 Yantai Dongcheng Pharmaceutical Heparin Sodium API Company Information
- 4.7.2 Yantai Dongcheng Pharmaceutical Heparin Sodium API Business Overview
- 4.7.3 Yantai Dongcheng Pharmaceutical Heparin Sodium API Production Capacity, Value and Gross Margin (2021-2026)
- 4.7.4 Yantai Dongcheng Pharmaceutical Product Portfolio
- 4.7.5 Yantai Dongcheng Pharmaceutical Recent Developments
- 4.8 Shenzhen Hepalink Pharmaceutical
- 4.8.1 Shenzhen Hepalink Pharmaceutical Heparin Sodium API Company Information
- 4.8.2 Shenzhen Hepalink Pharmaceutical Heparin Sodium API Business Overview
- 4.8.3 Shenzhen Hepalink Pharmaceutical Heparin Sodium API Production Capacity, Value and Gross Margin (2021-2026)
- 4.8.4 Shenzhen Hepalink Pharmaceutical Product Portfolio
- 4.8.5 Shenzhen Hepalink Pharmaceutical Recent Developments
- 4.9 Hubei Enoray Biopharmaceutical
- 4.9.1 Hubei Enoray Biopharmaceutical Heparin Sodium API Company Information
- 4.9.2 Hubei Enoray Biopharmaceutical Heparin Sodium API Business Overview
- 4.9.3 Hubei Enoray Biopharmaceutical Heparin Sodium API Production Capacity, Value and Gross Margin (2021-2026)
- 4.9.4 Hubei Enoray Biopharmaceutical Product Portfolio
- 4.9.5 Hubei Enoray Biopharmaceutical Recent Developments
- 4.10 Nanjing King-friend Biochemical Pharmaceutical
- 4.10.1 Nanjing King-friend Biochemical Pharmaceutical Heparin Sodium API Company Information
- 4.10.2 Nanjing King-friend Biochemical Pharmaceutical Heparin Sodium API Business Overview
- 4.10.3 Nanjing King-friend Biochemical Pharmaceutical Heparin Sodium API Production Capacity, Value and Gross Margin (2021-2026)
- 4.10.4 Nanjing King-friend Biochemical Pharmaceutical Product Portfolio
- 4.10.5 Nanjing King-friend Biochemical Pharmaceutical Recent Developments
- 4.11 Qingdao Jiulong Biopharmaceutical
- 4.11.1 Qingdao Jiulong Biopharmaceutical Heparin Sodium API Company Information
- 4.11.2 Qingdao Jiulong Biopharmaceutical Heparin Sodium API Business Overview
- 4.11.3 Qingdao Jiulong Biopharmaceutical Heparin Sodium API Production Capacity, Value and Gross Margin (2021-2026)
- 4.11.4 Qingdao Jiulong Biopharmaceutical Product Portfolio
- 4.11.5 Qingdao Jiulong Biopharmaceutical Recent Developments
- 4.12 Changzhou Qianhong Biopharma
- 4.12.1 Changzhou Qianhong Biopharma Heparin Sodium API Company Information
- 4.12.2 Changzhou Qianhong Biopharma Heparin Sodium API Business Overview
- 4.12.3 Changzhou Qianhong Biopharma Heparin Sodium API Production Capacity, Value and Gross Margin (2021-2026)
- 4.12.4 Changzhou Qianhong Biopharma Product Portfolio
- 4.12.5 Changzhou Qianhong Biopharma Recent Developments
- 4.13 Dongying Tiandong Pharmaceutical
- 4.13.1 Dongying Tiandong Pharmaceutical Heparin Sodium API Company Information
- 4.13.2 Dongying Tiandong Pharmaceutical Heparin Sodium API Business Overview
- 4.13.3 Dongying Tiandong Pharmaceutical Heparin Sodium API Production Capacity, Value and Gross Margin (2021-2026)
- 4.13.4 Dongying Tiandong Pharmaceutical Product Portfolio
- 4.13.5 Dongying Tiandong Pharmaceutical Recent Developments
- 4.14 Nanjing Xinbai Pharmaceutical
- 4.14.1 Nanjing Xinbai Pharmaceutical Heparin Sodium API Company Information
- 4.14.2 Nanjing Xinbai Pharmaceutical Heparin Sodium API Business Overview
- 4.14.3 Nanjing Xinbai Pharmaceutical Heparin Sodium API Production Capacity, Value and Gross Margin (2021-2026)
- 4.14.4 Nanjing Xinbai Pharmaceutical Product Portfolio
- 4.14.5 Nanjing Xinbai Pharmaceutical Recent Developments
- 4.15 Yino Pharma
- 4.15.1 Yino Pharma Heparin Sodium API Company Information
- 4.15.2 Yino Pharma Heparin Sodium API Business Overview
- 4.15.3 Yino Pharma Heparin Sodium API Production Capacity, Value and Gross Margin (2021-2026)
- 4.15.4 Yino Pharma Product Portfolio
- 4.15.5 Yino Pharma Recent Developments
5 Global Heparin Sodium API Production by Region
- 5.1 Global Heparin Sodium API Production Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.2 Global Heparin Sodium API Production by Region: 2021-2032
- 5.2.1 Global Heparin Sodium API Production by Region: 2021-2026
- 5.2.2 Global Heparin Sodium API Production Forecast by Region (2027-2032)
- 5.3 Global Heparin Sodium API Production Value Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.4 Global Heparin Sodium API Production Value by Region: 2021-2032
- 5.4.1 Global Heparin Sodium API Production Value by Region: 2021-2026
- 5.4.2 Global Heparin Sodium API Production Value Forecast by Region (2027-2032)
- 5.5 Global Heparin Sodium API Market Price Analysis by Region (2021-2026)
- 5.6 Global Heparin Sodium API Production and Value, YOY Growth
- 5.6.1 North America Heparin Sodium API Production Value Estimates and Forecasts (2021-2032)
- 5.6.2 Europe Heparin Sodium API Production Value Estimates and Forecasts (2021-2032)
- 5.6.3 China Heparin Sodium API Production Value Estimates and Forecasts (2021-2032)
- 5.6.4 Japan Heparin Sodium API Production Value Estimates and Forecasts (2021-2032)
6 Global Heparin Sodium API Consumption by Region
- 6.1 Global Heparin Sodium API Consumption Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 6.2 Global Heparin Sodium API Consumption by Region (2021-2032)
- 6.2.1 Global Heparin Sodium API Consumption by Region: 2021-2026
- 6.2.2 Global Heparin Sodium API Forecasted Consumption by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Heparin Sodium API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Heparin Sodium API Consumption by Country (2021-2032)
- 6.3.3 United States
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Heparin Sodium API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Heparin Sodium API Consumption by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Russia
- 6.4.8 Spain
- 6.4.9 Netherlands
- 6.4.10 Switzerland
- 6.4.11 Sweden
- 6.4.12 Poland
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Heparin Sodium API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Heparin Sodium API Consumption by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 India
- 6.5.7 Australia
- 6.5.8 Taiwan
- 6.5.9 Southeast Asia
- 6.6 South America, Middle East & Africa
- 6.6.1 South America, Middle East & Africa Heparin Sodium API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East & Africa Heparin Sodium API Consumption by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 Argentina
- 6.6.5 Chile
- 6.6.6 Turkey
- 6.6.7 GCC Countries
7 Segment by Type
- 7.1 Global Heparin Sodium API Production by Type (2021-2032)
- 7.1.1 Global Heparin Sodium API Production by Type (2021-2032) & (t)
- 7.1.2 Global Heparin Sodium API Production Market Share by Type (2021-2032)
- 7.2 Global Heparin Sodium API Production Value by Type (2021-2032)
- 7.2.1 Global Heparin Sodium API Production Value by Type (2021-2032) & (US$ Million)
- 7.2.2 Global Heparin Sodium API Production Value Market Share by Type (2021-2032)
- 7.3 Global Heparin Sodium API Price by Type (2021-2032)
8 Segment by Application
- 8.1 Global Heparin Sodium API Production by Application (2021-2032)
- 8.1.1 Global Heparin Sodium API Production by Application (2021-2032) & (t)
- 8.1.2 Global Heparin Sodium API Production Market Share by Application (2021-2032)
- 8.2 Global Heparin Sodium API Production Value by Application (2021-2032)
- 8.2.1 Global Heparin Sodium API Production Value by Application (2021-2032) & (US$ Million)
- 8.2.2 Global Heparin Sodium API Production Value Market Share by Application (2021-2032)
- 8.3 Global Heparin Sodium API Price by Application (2021-2032)
9 Value Chain and Sales Channels Analysis of the Market
- 9.1 Heparin Sodium API Value Chain Analysis
- 9.1.1 Heparin Sodium API Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Heparin Sodium API Production Mode & Process
- 9.2 Heparin Sodium API Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Heparin Sodium API Distributors
- 9.2.3 Heparin Sodium API Customers
10 Global Heparin Sodium API Analyzing Market Dynamics
- 10.1 Heparin Sodium API Industry Trends
- 10.2 Heparin Sodium API Industry Drivers
- 10.3 Heparin Sodium API Industry Opportunities and Challenges
- 10.4 Heparin Sodium API Industry Restraints
11 Report Conclusion
12 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst